"MDIs are most often used as rescue medications during acute attacks. Improper dosing and other misuses can lead to negative outcomes, such as the exacerbation of symptoms and even hospitalization," says Gary Cantrell, TEAMM Executive Vice President of Sales and Marketing. "But with MD Turbo physicians will be able to prescribe their drug of choice in combination with an easy to use, handheld, breath-activated device to overcome the delivery challenges often facing their patients."
According to three independent studies spanning more than 10 years, greater than 50% of patients using traditional press-and-breathe MDIs to control asthma or Chronic Obstructive Pulmonary Disease (COPD), regardless of age or MDI experience, cannot successfully coordinate the press-and-breathe action necessary for drug delivery to the lungs.1,2,3 Further, at least one additional study showed that more than 70% of MDI users do not know the number of doses remaining in their inhalers at a given time.4
"MDIs have been around for about 50 years. But MD Turbo is the first companion product to solve two of the biggest challenges facing MDI users: coordination of inhaler actuation with patient's breath, and the accounting of how much medication is left in the inhaler," says Gil Mott, President and Chief Executive Officer of Respiric
'"/>
Contact: Adam Holdsworth
aholdsworth@investorrelationsgroup.com
212-825-3210
The Investor Relations Group
11-Apr-2006